This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia Open Access 28 April 2016
-
Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
Cases Journal Open Access 26 May 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kantarjian HM, Talpaz M . Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias Semin Oncol 2001 5: 9–18
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037
Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options Blood 2001 98: 2039–2042
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 2002 346: 645–652
Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ . STI571: a paradigm of new agents for cancer therapeutics J Clin Oncol 2002 20: 325–334
Burton C, Azzi A, Kerridge I . Adverse events after imatinib mesylate therapy N Engl J Med 2002 346: 712–713
Elliott MA, Mesa RA, Tefferi A . Adverse events after imatinib mesylate therapy N Engl J Med 2002 346: 713
O'Brien SG, Peng B, Dutrix C, Mehring G, Milosavljev S, Capdeville R, Fischer T . A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate, in a patients with chronic myeloid leukemia Blood 2001 98 (Suppl.): 141a (593)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohyashiki, K., Kuriyama, Y., Nakajima, A. et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16, 2160–2161 (2002). https://doi.org/10.1038/sj.leu.2402702
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402702
This article is cited by
-
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Molecular and Cellular Biochemistry (2022)
-
Drug-Induced Liver Injury—Perspectives from Pathology
Current Pharmacology Reports (2018)
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia (2016)
-
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Nature Reviews Clinical Oncology (2016)
-
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Drug Safety (2013)